Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Four-Period Cross-Over Phase I Study to Assess Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs in Healthy Volunteers

NCT05857384 is registered in ClinicalTrials.gov with Incannex Healthcare Ltd as lead sponsor.

NCT NCT05857384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05857384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Four-Period Cross-Over Phase I Study to Assess Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs in Healthy Volunteers
Lead sponsor
Incannex Healthcare Ltd
Phase
Phase 1
Overall status
Completed
Start date
September 8, 2023
Completion date
July 31, 2024
Enrollment
125 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

obstructive sleep apnea